Tumor resection

PROCEDURE16 trials

Sponsors

University of Tennessee, Ann & Robert H Lurie Children's Hospital of Chicago, Eben Rosenthal, Hospital Sirio-Libanes, Centre Leon Berard

Conditions

Adult Soft Tissue SarcomaAnaplastic EpendymomaAnaplastic OligodendrogliomaAstrocytoma, Grade IIIAstrocytoma, IDH-Mutant, Grade 3Astrocytoma, IDH-Mutant, Grade 4Brain NeoplasmClear Cell Ependymoma

Phase 1

Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine

TerminatedNCT02722512

Ann & Robert H Lurie Children's Hospital of ChicagoAnaplastic Ependymoma, Astrocytoma, Grade III, Clear Cell Ependymoma +2

Start: 2016-07-31End: 2019-11-13Updated: 2025-02-18

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

TerminatedNCT02855086

Eben RosenthalBrain Neoplasm, Malignant Glioma

Start: 2016-10-31End: 2016-11-22Updated: 2020-03-31

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

TerminatedNCT06338657

University of Southern CaliforniaHead and Neck Squamous Cell Carcinoma

Start: 2024-04-01End: 2025-09-09Updated: 2025-09-16

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

RecruitingNCT06914479

University of Michigan Rogel Cancer CenterRecurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm

Start: 2026-06-01End: 2031-06-01Target: 11Updated: 2026-03-11

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

RecruitingNCT07288112

Diakonos Oncology CorporationRefractory Melanoma

Start: 2026-02-23End: 2033-01-01Target: 35Updated: 2026-02-23

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Not yet recruitingNCT07468136

Mayo ClinicAnaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 +3

Start: 2026-04-24End: 2030-10-25Target: 33Updated: 2026-03-12

Phase 2

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

RecruitingNCT06151847

University of Kansas Medical CenterClinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +1

Start: 2023-12-21End: 2025-11-27Target: 12Updated: 2024-02-28

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

RecruitingNCT06805305

Diakonos Oncology CorporationGlioblastoma (GBM)

Start: 2025-03-17End: 2032-03-01Target: 180Updated: 2026-03-24

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

RecruitingNCT06980038

National Cancer Institute (NCI)Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma +19

Start: 2026-08-21End: 2027-11-24Target: 44Updated: 2026-04-03

Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

RecruitingNCT06172296

National Cancer Institute (NCI)Ganglioneuroblastoma, Nodular, Neuroblastoma

Start: 2024-04-19End: 2029-12-31Target: 478Updated: 2026-04-03

Unknown Phase

Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer

WithdrawnNCT00347256

University of TennesseeParanasal Sinus Neoplasms

Target: 60Updated: 2008-12-10

Glioma Microenvironment an Exploratory Study

Active, not recruitingNCT03189420

Hospital Sirio-LibanesGlioma of Brain

Start: 2016-10-31End: 2026-12-31Target: 30Updated: 2024-04-19

Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma

Centre Leon BerardAdult Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma

Start: 2023-04-21End: 2024-01-31Target: 25Updated: 2023-10-30

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

RecruitingNCT06146725

Jasper GerritsenGlioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme +2

Start: 2023-01-01End: 2029-01-01Target: 564Updated: 2023-11-27

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

RecruitingNCT06146738

Jasper GerritsenGlioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme +1

Start: 2023-01-01End: 2029-01-01Target: 1015Updated: 2023-11-27

Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer.

Enrolling by invitationNCT06629233

University GhentEstrogen Receptor Positive Breast Cancer

Start: 2024-09-25End: 2025-12-31Target: 36Updated: 2025-08-29

Related Papers

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma

medRxiv2026-04-02

Reduced dose fludarabine and cyclophosphamide lymphodepletion before tumor-infiltrating lymphocyte therapy in melanoma

Future Oncology2025-05-091 citations

Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202)

BMJ Open2024-09-012 citations

Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144, lifileucel) in metastatic melanoma.

Journal of Clinical Oncology2024-06-013 citations